دورية أكاديمية
أعرض في EDS

Risk Factors and Nomogram Model for Hepatocellular Carcinoma Development in Chronic Hepatitis B Patients with Low-Level Viremia.

التفاصيل البيبلوغرافية
العنوان: Risk Factors and Nomogram Model for Hepatocellular Carcinoma Development in Chronic Hepatitis B Patients with Low-Level Viremia.
المؤلفون: Chen YC; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Chi Mei Medical Center, Yongkang District, Tainan, Taiwan.; Department of Internal Medicine, Chi Mei Medical Center, Yongkang District, Tainan, Taiwan., Yang CC; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Chi Mei Medical Center, Yongkang District, Tainan, Taiwan., Kuo HT; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Chi Mei Medical Center, Yongkang District, Tainan, Taiwan., Sheu MJ; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Chi Mei Medical Center, Yongkang District, Tainan, Taiwan., Feng IC; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Chi Mei Medical Center, Yongkang District, Tainan, Taiwan., Liu CF; Department of Medical Research, Chi Mei Medical Center, Tainan, Taiwan., Sun CS; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Chi Mei Medical Center, Yongkang District, Tainan, Taiwan., Wang SH; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Chi Mei Medical Center, Yongkang District, Tainan, Taiwan., Lin CY; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Chi Mei Medical Center, Yongkang District, Tainan, Taiwan., Chen CH; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Chi Mei Medical Center, Yongkang District, Tainan, Taiwan., Lin SH; Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan.; Department of Public Health, College of Medicine, National Cheng Kung University, Tainan, Taiwan.; Biostatistics Consulting Center, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
المصدر: International journal of medical sciences [Int J Med Sci] 2024 Jun 17; Vol. 21 (9), pp. 1661-1671. Date of Electronic Publication: 2024 Jun 17 (Print Publication: 2024).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Ivyspring International Publisher Country of Publication: Australia NLM ID: 101213954 Publication Model: eCollection Cited Medium: Internet ISSN: 1449-1907 (Electronic) Linking ISSN: 14491907 NLM ISO Abbreviation: Int J Med Sci Subsets: MEDLINE
أسماء مطبوعة: Original Publication: [Australia] : Ivyspring International Publisher, c2004-
مواضيع طبية MeSH: Carcinoma, Hepatocellular*/virology , Carcinoma, Hepatocellular*/epidemiology , Carcinoma, Hepatocellular*/pathology , Liver Neoplasms*/virology , Liver Neoplasms*/epidemiology , Liver Neoplasms*/etiology , Hepatitis B, Chronic*/complications , Hepatitis B, Chronic*/virology , Nomograms* , Viremia*/complications , Hepatitis B virus*/isolation & purification, Humans ; Male ; Female ; Middle Aged ; Retrospective Studies ; Risk Factors ; Adult ; Antiviral Agents/therapeutic use ; Incidence ; DNA, Viral/blood
مستخلص: Background and aim: Patients with chronic hepatitis B patients (CHB) with low-level viremia (LLV) are not necessarily at low risk of developing hepatocellular carcinoma (HCC). The question of whether CHB patients with LLV require immediate antiviral agent (AVT) or long-term AVT remains controversial. The study aims to investigate the risk of HCC development and the risk factors in CHB patients with LLV and construct a nomogram model predicting the risk of HCC. Methods: We conducted a retrospective cohort study that enrolled 16,895 CHB patients from January 2008 to December 2020. The patients were divided into three groups for comparison: the LLV group, maintained virological response (MVR) group and HBV-DNA>2000 group. The cumulative incidence of progression to HCC was assessed. Cox regression analysis was performed to determine the final risk factors, and a nomogram model was constructed. The 10-fold Cross-Validation method was utilized for internal validation. Results: A total of 408 new cases of HCC occurred during the average follow-up period of 5.78 years. The 3, 5, and 10-year cumulative HCC risks in the LLV group were 3.56%, 4.96%, and 9.51%, respectively. There was a significant difference in the cumulative risk of HCC between the HBV-DNA level > 2000 IU/mL and LLV groups (p = 0.049). Independent risk factors for HCC development in LLV group included male gender, age, presence of cirrhosis, and platelets count. The Area Under the Curve (AUC) values for the 3-year and 5-year prediction from our HCC risk prediction model were 0.75 and 0.76, respectively. Conclusion: Patients with LLV and MVR are still at risk for developing HCC. The nomogram established for CHB patient with LLV, incorporating identified significant risk factors, serves as an effective tool for predicting HCC-free outcomes. This nomogram model provides valuable information for determining appropriate surveillance strategies and prescribing AVT.
Competing Interests: Competing Interests: The authors have declared that no competing interest exists.
(© The author(s).)
References: Hepatology. 2023 May 1;77(5):1746-1756. (PMID: 36633913)
Dig Dis Sci. 2019 Aug;64(8):2327-2337. (PMID: 30830520)
J Hepatol. 2020 Feb;72(2):250-261. (PMID: 31954490)
JAMA Surg. 2016 Apr;151(4):356-63. (PMID: 26579636)
Am J Gastroenterol. 2022 Feb 1;117(2):288-294. (PMID: 34506308)
Lancet. 2013 Feb 9;381(9865):468-75. (PMID: 23234725)
Liver Int. 2021 Jun;41 Suppl 1:9-14. (PMID: 34155802)
Lancet. 2014 May 17;383(9930):1749-61. (PMID: 24480518)
JAMA. 2006 Jan 4;295(1):65-73. (PMID: 16391218)
J Viral Hepat. 2019 Dec;26(12):1465-1472. (PMID: 31332935)
Int J Mol Sci. 2019 Mar 18;20(6):. (PMID: 30889843)
J Hepatol. 2017 Aug;67(2):370-398. (PMID: 28427875)
Am J Gastroenterol. 2006 Aug;101(8):1797-803. (PMID: 16817842)
PLoS One. 2012;7(1):e29179. (PMID: 22235270)
Hepatol Int. 2016 Jan;10(1):1-98. (PMID: 26563120)
JAMA Oncol. 2017 Dec 1;3(12):1683-1691. (PMID: 28983565)
Liver Int. 2018 Nov;38(11):1930-1939. (PMID: 29654711)
J Gastroenterol Hepatol. 2011 Apr;26(4):628-38. (PMID: 21323729)
Clin Gastroenterol Hepatol. 2021 Dec;19(12):2499-2513. (PMID: 33667678)
J Hepatol. 2020 Oct;73(4):855-862. (PMID: 32360997)
Gastroenterology. 1992 Nov;103(5):1630-5. (PMID: 1426884)
J Gastroenterol Hepatol. 2013 Jan;28(1):10-7. (PMID: 23094699)
Hepatol Int. 2017 Jul;11(4):317-370. (PMID: 28620797)
Brief Bioinform. 2011 May;12(3):203-14. (PMID: 21324971)
Hepatol Int. 2017 Jan;11(1):1-30. (PMID: 27714681)
J Clin Transl Hepatol. 2021 Dec 28;9(6):850-859. (PMID: 34966648)
N Engl J Med. 2023 Jan 5;388(1):55-69. (PMID: 36599063)
J Natl Cancer Inst. 2008 Aug 20;100(16):1134-43. (PMID: 18695135)
J Natl Cancer Inst. 2005 Feb 16;97(4):265-72. (PMID: 15713961)
N Engl J Med. 2017 Aug 24;377(8):756-768. (PMID: 28834467)
Int J Med Inform. 2021 May;149:104429. (PMID: 33647600)
J Clin Med. 2021 May 22;10(11):. (PMID: 34067473)
Lancet Gastroenterol Hepatol. 2019 Jul;4(7):545-558. (PMID: 30981686)
Hepatology. 2018 Apr;67(4):1560-1599. (PMID: 29405329)
J Viral Hepat. 2005 Jul;12(4):373-9. (PMID: 15985007)
Hepatology. 2017 Aug;66(2):335-343. (PMID: 28012257)
Hepatology. 2015 Sep;62(3):694-701. (PMID: 25963803)
Cancers (Basel). 2020 Jun 22;12(6):. (PMID: 32580490)
J Viral Hepat. 2018 Oct;25(10):1161-1171. (PMID: 29741286)
فهرسة مساهمة: Keywords: HBV; HCC; Low viral load; Taiwan; nomogram
المشرفين على المادة: 0 (Antiviral Agents)
0 (DNA, Viral)
تواريخ الأحداث: Date Created: 20240715 Date Completed: 20240715 Latest Revision: 20240716
رمز التحديث: 20240716
مُعرف محوري في PubMed: PMC11241087
DOI: 10.7150/ijms.95861
PMID: 39006848
قاعدة البيانات: MEDLINE
الوصف
تدمد:1449-1907
DOI:10.7150/ijms.95861